THE DEFINITIVE GUIDE TO CANAGLIFLOZIN

There have been no clinically considerable discrepancies while in the pharmacokinetics of possibly midazolam (CYP3A4 substrate) or repaglinide (CYP2C8 substrate) when utilised concomitantly with finerenone. Several doses of 40 mg finerenone once-each day had no clinically related impact on AUC or Cmax of the BCRP and OATP substrate rosuvastatin.To